Right Decisions
Infectious diseases
COVID-19 treatment guidelines (hospitalised adults)
Back
Antivirals
Molnupiravir (Lageviro®)

Update your RDS mobile app to v4.7.2 to download toolkits even when website is down.

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. You will see that each toolkit has a small QR code icon in the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively update to the latest release - RDS app version 4.7.1 - to see this improvement.

Updating to this latest version of the RDS app is also strongly recommended to get the full benefits of the new resilience arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Molnupiravir (Lageviro®)

Infectious diseases

NHS Lothian

Consider a 5-day course of molnupiravir for adults with COVID-19 who:

do not need supplemental oxygen for COVID-19 and
are within 5 days of symptom onset and
are thought to be at high risk of progression to severe COVID-19 (See list included in this document and NICE TA878) and
where nirmatrelvir/ritonavir (Paxlovid^®) is contraindicated or unsuitable.

When assessing the person, take into account their likely response to any vaccinations already given, any comorbidities or risk factors, and whether their condition is deteriorating.

Do not offer molnupiravir to children and young people aged under 18, or pregnant women.

Dosing

The recommended dose of molnupiravir is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days.

For contraindications, cautions and interactions please consult the SmPC and BNF.